Literature DB >> 26529120

Potent Human Telomerase Inhibitors: Molecular Dynamic Simulations, Multiple Pharmacophore-Based Virtual Screening, and Biochemical Assays.

Faezeh Shirgahi Talari1,2, Kowsar Bagherzadeh3, Sahand Golestanian1, Michael Jarstfer2, Massoud Amanlou1.   

Abstract

Telomere maintenance is a universal cancer hallmark, and small molecules that disrupt telomere maintenance generally have anticancer properties. Since the vast majority of cancer cells utilize telomerase activity for telomere maintenance, the enzyme has been considered as an anticancer drug target. Recently, rational design of telomerase inhibitors was made possible by the determination of high resolution structures of the catalytic telomerase subunit from a beetle and subsequent molecular modeling of the human telomerase complex. A hybrid strategy including docking, pharmacophore-based virtual screening, and molecular dynamics simulations (MDS) were used to identify new human telomerase inhibitors. Docking methodology was applied to investigate the ssDNA telomeric sequence and two well-known human telomerase inhibitors' (BIBR1532 and MST-312) modes of interactions with hTERT TEN domain. Subsequently molecular dynamic simulations were performed to monitor and compare hTERT TEN domain, TEN-ssDNA, TEN-BIBR1532, TEN-MST-312, and TEN-ssDNA-BIBR1532 behavior in a dynamic environment. Pharmacophore models were generated considering the inhibitors manner in the TEN domain anchor site. These exploratory studies identified several new potent inhibitors whose IC50 values were generated experimentally in a low micromolar range with the aid of biochemical assays, including both the direct telomerase and the telomeric repeat amplification protocol (TRAP) assays. The results suggest that the current models of human telomerase are useful templates for rational inhibitor design.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26529120     DOI: 10.1021/acs.jcim.5b00336

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  6 in total

1.  Combining molecular dynamics simulation and ligand-receptor contacts analysis as a new approach for pharmacophore modeling: beta-secretase 1 and check point kinase 1 as case studies.

Authors:  Ma'mon M Hatmal; Shadi Jaber; Mutasem O Taha
Journal:  J Comput Aided Mol Des       Date:  2016-10-08       Impact factor: 3.686

2.  Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells.

Authors:  Andrea Celeghin; Silvia Giunco; Riccardo Freguja; Manuela Zangrossi; Silvia Nalio; Riccardo Dolcetti; Anita De Rossi
Journal:  Cell Death Dis       Date:  2016-12-29       Impact factor: 8.469

Review 3.  Application of computational methods for anticancer drug discovery, design, and optimization.

Authors:  Diego Prada-Gracia; Sara Huerta-Yépez; Liliana M Moreno-Vargas
Journal:  Bol Med Hosp Infant Mex       Date:  2016-11-30

4.  Synthesis, molecular docking, and antiepileptic activity of novel phthalimide derivatives bearing amino acid conjugated anilines.

Authors:  Azar Asadollahi; Mehdi Asadi; Faezeh Sadat Hosseini; Zeinab Ekhtiari; Mahmood Biglar; Massoud Amanlou
Journal:  Res Pharm Sci       Date:  2019-12-11

5.  Anti-Proliferative and Pro-Apoptotic Effects of Short-Term Inhibition of Telomerase In Vivo and in Human Malignant B Cells Xenografted in Zebrafish.

Authors:  Silvia Giunco; Manuela Zangrossi; Francesca Dal Pozzolo; Andrea Celeghin; Giovanni Ballin; Maria Raffaella Petrara; Aamir Amin; Francesco Argenton; Miguel Godinho Ferreira; Anita De Rossi
Journal:  Cancers (Basel)       Date:  2020-07-25       Impact factor: 6.639

Review 6.  Extra-telomeric functions of telomerase in the pathogenesis of Epstein-Barr virus-driven B-cell malignancies and potential therapeutic implications.

Authors:  Silvia Giunco; Maria Raffaella Petrara; Manuela Zangrossi; Andrea Celeghin; Anita De Rossi
Journal:  Infect Agent Cancer       Date:  2018-04-10       Impact factor: 2.965

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.